Characteristics | Week 12 | Week 24 | ||||
---|---|---|---|---|---|---|
β (95% CI) | Wald χ2 | p-value | β (95% CI) | Wald χ2 | p-value | |
Treatment group (Group 1 vs. Group 2) | 1.07 (0.45–2.56) | 0.021 | 0.884 | 0.88 (0.38–2.02) | 0.088 | 0.767 |
Sex (female vs. male) | 0.89 (0.34–2.35) | 0.055 | 0.815 | 0.90 (0.38–2.14) | 0.059 | 0.808 |
Age at recruitment (year) | 0.97 (0.94–1.01) | 1.911 | 0.167 | 0.98 (0.94–1.01) | 1.899 | 0.168 |
Body weight (kg) | 0.99 (0.95–1.02) | 0.624 | 0.430 | 0.99 (0.95–1.03) | 0.326 | 0.568 |
Alcohol use disorder | 2.07 (0.58–7.42) | 1.235 | 0.266 | 1.48 (0.46–4.78) | 0.430 | 0.512 |
Number of physical comorbidities | 1.28 (1.01–1.62) | 4.303 | 0.038* | 1.21 (0.96–1.53) | 2.581 | 0.108 |
α-fetoprotein level (ng/mL) | 1.00 (0.99–1.02) | 0.123 | 0.726 | 0.98 (0.94–1.01) | 2.403 | 0.121 |
Genotype of HCV (non- 1 vs. 1) | 0.66 (0.27–1.63) | 0.801 | 0.371 | 0.70 (0.28–1.72) | 0.615 | 0.433 |
Ribavirin daily dose (g/day) | 1.20 (0.24–6.00) | 0.052 | 0.820 | 1.95 (0.67–5.64) | 1.505 | 0.220 |
Poor treatment response (HCV RNA positive) | 1.45 (0.60–3.50) | 0.669 | 0.414 | 1.53 (0.61–3.82) | 0.832 | 0.362 |